Appointment of Nominated Adviser and Broker

Diaceutics PLC
02 September 2024
 

Appointment of Nominated Adviser and Broker

 

Belfast and London, 2 September 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry is pleased to announce the appointment of Canaccord Genuity Limited as the Company's Nominated Adviser and Broker, with immediate effect.

 

Enquiries: 


Diaceutics PLC   


Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer 

Tel: +44 (0)28 9040 6500

investorrelations@diaceutics.com

 

 

Canaccord Genuity Limited (Nomad & Broker) 

 

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees


 

Alma Strategic Communications

 

Tel: +44(0)20 3405 0205 

Caroline Forde, Kinvara Verdon

 

diaceutics@almastrategic.com

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
Investor Meets Company
UK 100